Pfizer Inc. (PFE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 10, 2025

$26.72

P/E Ratio

35.92

Market Cap

$151.42B

Description

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerPFE
  • Price$26.72-0.52%

Trading Information

  • Market cap$151.42B
  • Float99.97%
  • Average Daily Volume (1m)42,422,483
  • Average Daily Volume (3m)43,142,247
  • EPS$0.75

Company

  • Revenue$60.11B
  • Rev growth (1yr)33.78%
  • Net income$4.47B
  • Gross margin60.85%
  • EBITDA margin37.98%
  • EBITDA$6.72B
  • EV$223.98B
  • EV/Revenue3.73
  • P/E35.92
  • P/S2.54
  • P/B1.64
Documents
SEC Filings
8-K (2024-12-17)
8-K (2024-10-29)
8-K (2024-10-15)
8-K (2024-07-30)
8-K (2024-07-26)
8-K (2024-07-10)
8-K (2024-07-01)
8-K (2024-05-22)
8-K (2024-05-01)
8-K (2024-04-29)
8-K (2024-01-30)
8-K (2024-01-10)
8-K (2023-12-14)
8-K (2023-12-13)
8-K (2023-12-12)
8-K (2023-10-31)
8-K (2023-10-13)
8-K (2023-08-01)
8-K (2023-07-27)
8-K (2023-05-19)
8-K (2023-05-15)
8-K (2023-05-02)
8-K (2023-05-01)
8-K (2023-03-13)
8-K (2023-02-21)
8-K (2023-01-31)
10-Q (2024-11-04)
10-Q (2024-08-05)
10-Q (2024-05-08)
10-Q (2023-11-08)
10-Q (2023-08-09)
10-Q (2023-05-10)
10-K (2024-02-22)
10-K (2023-02-23)
Earnings Calls
Earnings Report 2025Q1
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-10-31)
Earnings Report (2023-08-01)
Factset Street Account
StreetAccount Consensus Metrics Preview - Pfizer Q3 Earnings ($30.73, 0.00) (2023-10-26T14:49:38Z)
Street Takeaways - Pfizer Amended Paxlovid US Government Supply Agreement ($32.64, -0.63) (2023-10-17T19:35:14Z)
Pfizer to price course of Paxlovid at close to $1,400 once commercial sales begin later this year -- wires ($31.41, 0.00) (2023-10-18T20:49:27Z)
Pfizer issues press release on previously disclosed FDA approval of Braftovi + Mektovi in certain NSCLC patients ($33.11, 0.00) (2023-10-12T10:49:13Z)
Pfizer announces topline Phase 2B results of oral GLP-1R agonist, danuglipron, in adults with obesity; study met its primary endpoint ($30.47, 0.00) (2023-12-01T12:01:21Z)
Pfizer announces 39 presentations regarding the treatment of hemophilia, sickle cell disease, and blood cancers at ASH ($30.33, -0.19) (2023-11-02T15:01:18Z)
Pfizer amends US government Paxlovid supply agreement and updates full-year 2023 guidance ($32.11, 0.00) (2023-10-13T20:31:53Z)
NICE recommends Pfizer's Xeljanz to treat active ankylosing spondylitis (2023-10-19T04:13:07Z)
Follow-up: Pfizer to price course of Paxlovid at $1,390 once commercial sales begin later this year - CNBC, citing company spokesperson ($31.41, 0.00) (2023-10-18T22:35:50Z)
Follow-up: Pfizer announces topline Phase 2B results of oral GLP-1R agonist, danuglipron, in adults with obesity; at this time, twice-daily danuglipron formulation will not advance into Phase 3 studies ($30.47, 0.00) (2023-12-01T12:00:31Z)
Follow-up: Pfizer amends Paxlovid US gov supply agreement, updates FY23 guidance, commercialization plans, cost realignment program; call Monday at 8:00ET ($32.11, 0.00) (2023-10-13T20:44:59Z)
EU's CHMP adopted a positive opinion recommending the granting of a conditional marketing authorisation for Elrexfio ($32.92, 0.00) (2023-10-13T11:40:09Z)
Factset
Factset Business Description
Wikipedia
Pfizer_Inc.